About ACT Genomics
ACT Genomics is a company based in Taipei (Taiwan) founded in 2014 by Joe Hsueh and Shu Jen Chen was acquired by Delta Electronics in June 2025. ACT Genomics has raised $20.5 million across 4 funding rounds from investors including Prenetics, Delta Electronics and CLSA Capital Partners. ACT Genomics has completed 1 acquisition, including MC Diagnostics. ACT Genomics operates in a competitive market with competitors including Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.
- Headquarter Taipei, Taiwan
- Founders Joe Hsueh, Shu Jen Chen
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$20.5 M (USD)
in 4 rounds
-
Latest Funding Round
Not available
-
Investors
Prenetics
& 9 more
-
Employee Count
Not available
- Investments & Acquisitions
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of ACT Genomics
Unlock access to complete
CTO Team
1 people
CSO Team
1 people
Finance and Accounting
1 people
Software Development Team
1 people
Unlock access to complete
Funding Insights of ACT Genomics
ACT Genomics has successfully raised a total of $20.5M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ACT Genomics
ACT Genomics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Prenetics, Delta Electronics and CLSA Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are made in university research startups.
|
Locked | Locked | Locked | |
|
Investments in early to late-stage tech startups are managed.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on AI, IoT, cloud, agriculture, healthcare, biotech, e-commerce, and multiple sectors
|
Locked | Locked | Locked |
Investor details for ACT Genomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ACT Genomics
ACT Genomics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include MC Diagnostics.
Investment portfolio details for ACT Genomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Molecular diagnostics automation systems
|
Locked | Locked | 2006 | Locked |
Complete acquisition details for ACT Genomics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - ACT Genomics
Detailed financials for ACT Genomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Act Genomics Comparisons
Peer comparison for ACT Genomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ACT Genomics
ACT Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
Genomic sequencing and diagnosis software is provided for healthcare.
|
Detailed competitors of ACT Genomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Act Genomics
Complete news archive for ACT Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ACT Genomics
ACT Genomics was founded in 2014 and raised its 1st funding round 1 year after it was founded.
ACT Genomics is headquartered in Taipei, Taiwan.
ACT Genomics is a funded company, having raised a total of $20.5M across 4 funding rounds to date.
ACT Genomics was founded in 2014 in Taipei, Taiwan, focusing on the genomics sector for cancer applications. Clinical services include next-generation sequencing panels such as ACTImmune for auto-immune diseases, ACTColon for colon cancer, ACTGastric for gastric cancer, and ACTBreast for breast cancer. Pharmacogenomic panels like ACTDrug and ACTOnco are utilized to guide therapy based on patient genotypes. Custom genomic solutions are also extended to biopharma firms and research entities.
ACT Genomics's top competitors include Juno Therapeutics, Personalis and Poseida Therapeutics.
ACT Genomics has made 1 acquisition, including MC Diagnostics.
ACT Genomics has 10 investors. Key investors include Prenetics, Delta Electronics, CLSA Capital Partners, Hotung Investment Holdings, and Hua Nan Financial Holdings.